Ami M Kabadi1, Leah Machlin2, Nikita Dalal2, Rhianna E Lee3, Ian McDowell2, Nirav N Shah2, Lauren Drowley4, Scott H Randell5, Timothy E Reddy6. 1. Element Genomics, a UCB Pharma company, Durham, NC, USA. Electronic address: ami.kabadi@gmail.com. 2. Element Genomics, a UCB Pharma company, Durham, NC, USA. 3. Marsico Lung Institute, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Cell Biology and Physiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4. UCB Biosciences, Durham, NC, USA. 5. Marsico Lung Institute, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Cell Biology and Physiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: scott_randell@med.unc.edu. 6. Element Genomics, a UCB Pharma company, Durham, NC, USA; Department of Biostatistics and Bioinformatics, Duke University Medical School, Durham, NC, USA. Electronic address: tim.reddy@duke.edu.
Abstract
BACKGROUND: Mechanisms governing the diversity of CFTR gene expression throughout the body are complex. Multiple intronic and distal regulatory elements are responsible for regulating differential CFTR expression across tissues. METHODS: Drawing on published data, 18 high-priority genomic regions were identified and interrogated for CFTR-enhancer function using CRISPR/dCas9-based epigenome editing tools. Each region was evaluated by dCas9p300 and dCas9KRAB for its ability to enhance or repress CFTR expression, respectively. RESULTS: Multiple genomic regions were tested for enhancer activity using CRISPR/dCas9 epigenome editing. dCas9p300 mediates a significant increase in CFTR mRNA levels when targeted to the promoter and a region 44 kb upstream of the transcriptional start site in a CFTR-low expressing cell line. Multiple gRNAs targeting the promoter induced a robust increase in CFTR protein levels. In contrast, dCas9KRAB-mediated repression is much more robust with 10 of the 18 evaluated genomic regions inducing CFTR protein knockdown. To evaluate the therapeutic efficacy of modulating CFTR gene regulation, dCas9p300 was used to induce elevated levels of CFTR from the endogenous locus in ΔF508/ΔF508 human bronchial epithelial cells. Ussing chamber studies demonstrated a synergistic increase in ion transport in response to CRISPR-induced expression of ΔF508 CFTR mRNA along with VX809 treatment. CONCLUSIONS: CRISPR/dCas9-based epigenome-editing provides a previously unexplored tool for interrogating CFTR enhancer function. Here, we demonstrate that therapeutic interventions that increase the expression of CFTR may improve the efficacy of CFTR modulators. A better understanding CFTR regulatory mechanisms could uncover novel therapeutic interventions for the development of cystic fibrosis therapies.
BACKGROUND: Mechanisms governing the diversity of CFTR gene expression throughout the body are complex. Multiple intronic and distal regulatory elements are responsible for regulating differential CFTR expression across tissues. METHODS: Drawing on published data, 18 high-priority genomic regions were identified and interrogated for CFTR-enhancer function using CRISPR/dCas9-based epigenome editing tools. Each region was evaluated by dCas9p300 and dCas9KRAB for its ability to enhance or repress CFTR expression, respectively. RESULTS: Multiple genomic regions were tested for enhancer activity using CRISPR/dCas9 epigenome editing. dCas9p300 mediates a significant increase in CFTR mRNA levels when targeted to the promoter and a region 44 kb upstream of the transcriptional start site in a CFTR-low expressing cell line. Multiple gRNAs targeting the promoter induced a robust increase in CFTR protein levels. In contrast, dCas9KRAB-mediated repression is much more robust with 10 of the 18 evaluated genomic regions inducing CFTR protein knockdown. To evaluate the therapeutic efficacy of modulating CFTR gene regulation, dCas9p300 was used to induce elevated levels of CFTR from the endogenous locus in ΔF508/ΔF508 human bronchial epithelial cells. Ussing chamber studies demonstrated a synergistic increase in ion transport in response to CRISPR-induced expression of ΔF508 CFTR mRNA along with VX809 treatment. CONCLUSIONS: CRISPR/dCas9-based epigenome-editing provides a previously unexplored tool for interrogating CFTR enhancer function. Here, we demonstrate that therapeutic interventions that increase the expression of CFTR may improve the efficacy of CFTR modulators. A better understanding CFTR regulatory mechanisms could uncover novel therapeutic interventions for the development of cystic fibrosis therapies.
Authors: Martina Gentzsch; Susan E Boyles; Chaitra Cheluvaraju; Imron G Chaudhry; Nancy L Quinney; Crescentia Cho; Hong Dang; Xuefeng Liu; Richard Schlegel; Scott H Randell Journal: Am J Respir Cell Mol Biol Date: 2017-05 Impact factor: 6.914
Authors: Martin Jinek; Krzysztof Chylinski; Ines Fonfara; Michael Hauer; Jennifer A Doudna; Emmanuelle Charpentier Journal: Science Date: 2012-06-28 Impact factor: 47.728
Authors: M W Konstan; D R VanDevanter; S M Rowe; M Wilschanski; E Kerem; I Sermet-Gaudelus; E DiMango; P Melotti; J McIntosh; K De Boeck Journal: J Cyst Fibros Date: 2020-01-23 Impact factor: 5.527
Authors: Daniel T Montoro; Adam L Haber; Moshe Biton; Vladimir Vinarsky; Brian Lin; Susan E Birket; Feng Yuan; Sijia Chen; Hui Min Leung; Jorge Villoria; Noga Rogel; Grace Burgin; Alexander M Tsankov; Avinash Waghray; Michal Slyper; Julia Waldman; Lan Nguyen; Danielle Dionne; Orit Rozenblatt-Rosen; Purushothama Rao Tata; Hongmei Mou; Manjunatha Shivaraju; Hermann Bihler; Martin Mense; Guillermo J Tearney; Steven M Rowe; John F Engelhardt; Aviv Regev; Jayaraj Rajagopal Journal: Nature Date: 2018-08-01 Impact factor: 49.962
Authors: Pratiksha I Thakore; Anthony M D'Ippolito; Lingyun Song; Alexias Safi; Nishkala K Shivakumar; Ami M Kabadi; Timothy E Reddy; Gregory E Crawford; Charles A Gersbach Journal: Nat Methods Date: 2015-10-26 Impact factor: 28.547
Authors: Fidel Ramírez; Devon P Ryan; Björn Grüning; Vivek Bhardwaj; Fabian Kilpert; Andreas S Richter; Steffen Heyne; Friederike Dündar; Thomas Manke Journal: Nucleic Acids Res Date: 2016-04-13 Impact factor: 16.971
Authors: Max A Horlbeck; Luke A Gilbert; Jacqueline E Villalta; Britt Adamson; Ryan A Pak; Yuwen Chen; Alexander P Fields; Chong Yon Park; Jacob E Corn; Martin Kampmann; Jonathan S Weissman Journal: Elife Date: 2016-09-23 Impact factor: 8.140
Authors: Olga Villamizar; Shafagh A Waters; Tristan Scott; Sheena Saayman; Nicole Grepo; Ryan Urak; Alicia Davis; Adam Jaffe; Kevin V Morris Journal: Mol Ther Date: 2019-07-15 Impact factor: 11.454